The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

West Cancer Center opens its East Campus

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

WEST CANCER CENTER celebrated the grand opening of its East Campus location with a ribbon-cutting ceremony Nov. 17.

The 123,000 square foot facility combines West Cancer Center’s multispecialty services and clinical research program all at one location.

“This marks another milestone in the transformation of how we care for and treat our patients,” said Erich Mounce, CEO of West Cancer Center.

“By physically combining the forces of our multidisciplinary specialty teams into one facility, we are creating an environment that truly fosters collaboration and produces a unique understanding of what each specialty requires, allowing everyone to perform at their highest level.”

The opening is a result of a partnership between Methodist Healthcare, the University of Tennessee Health Science Center, and West Clinic, who joined together in January 2012 to form West Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account